Febrile Neutropenia Clinical Trial
Official title:
Antimicrobial Revision in Patients With Persistent Febrile Neutropenia: A Prospective, Randomized Trial
Febrile neutropenia is often seen in patients with hematologic malignancies who receive cytotoxic chemotherapy. These patients are usually placed on posaconazole prophylaxis upon starting chemotherapy. If an episode of febrile neutropenia occurs, generally an anti-pseudomonal beta lactam, like cefepime or piperacillin-tazobactam, is initiated. In patients who continue to fever on these agents, the optimal method of antimicrobial revision has yet to be determined.
In this prospective, randomized, open-label, single-center trial, the primary objective is to compare the clinical efficacy of two approaches to antimicrobial revision among patients with persistent febrile neutropenia. Neutropenic patients on cefepime or piperacillin-tazobactam who continue to fever for greater than 96 hours will be randomized to receive either meropenem or micafungin dosed according to local guidelines. The primary outcome is a global success rate including a composite of defervescence within 72 hours of meropenem or micafungin initiation, absence of signs or symptoms of infection, and no modification to antimicrobial regimen after initiation of meropenem or micafungin. The secondary outcomes to be collected include in-hospital mortality or discharge to hospice, hospital length of stay, time to defervescence, days of therapy of meropenem or micafungin, rate of Clostridioides difficile infection on meropenem or micafungin, and cause of any proven breakthrough infection while on meropenem or micafungin. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03641131 -
Ampholipad Real-World Data in Taiwan
|
||
| Not yet recruiting |
NCT02806557 -
Profiling Neutrophil Counts in Patients on Chemotherapy
|
N/A | |
| Completed |
NCT04914702 -
Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
|
||
| Completed |
NCT02728596 -
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
|
N/A | |
| Completed |
NCT03104595 -
Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02536599 -
Risk Factors & Outcomes for Clinically Documented Infections in Pediatric Cancer Patients With Fever & Neutropenia
|
||
| Completed |
NCT02005783 -
Study of Danggui Buxue Decoction in Preventing Neutropenia
|
Phase 2 | |
| Recruiting |
NCT03449693 -
Efficacy of Oral Supplementation With Magnesium to Reduce Febrile Neutropenia
|
Phase 2 | |
| Recruiting |
NCT05149547 -
mNGS Versus Blood Culture in FN
|
||
| Recruiting |
NCT05584930 -
Clusterin, Ptx3 and Pediatric Febrile Neutropenia (CluPPFeN)
|
N/A | |
| Completed |
NCT04134429 -
Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy
|
||
| Recruiting |
NCT01684189 -
Registry of Febrile Neutropenia and Invasive Fungal Infections
|
N/A | |
| Completed |
NCT00462878 -
Meropenem Versus Meropenem Plus Glycopeptide in Patients With Febrile Neutropenia After Allogenic Blood Stem Cell Transplantation
|
N/A | |
| Completed |
NCT00035425 -
Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection
|
Phase 3 | |
| Recruiting |
NCT04948463 -
Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia
|
Phase 4 | |
| Recruiting |
NCT03740464 -
Long-acting G-CSF for Febrile Neutropenia
|
Phase 3 | |
| Not yet recruiting |
NCT06116734 -
Lapelga vs Gastrofil
|
Phase 3 | |
| Completed |
NCT00503854 -
Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia
|
||
| Terminated |
NCT02732327 -
Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer
|
Phase 2 | |
| Completed |
NCT01114165 -
Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients
|
Phase 4 |